172 related articles for article (PubMed ID: 29664381)
21. Mycobacterium lepromatosis: emerging strain or species?
Levis WR; Zhang S; Martiniuk F
J Drugs Dermatol; 2012 Feb; 11(2):158. PubMed ID: 22402645
[No Abstract] [Full Text] [Related]
22. Analysis of cytokine production by Mycobacterium-reactive T cells. Failure to explain Mycobacterium leprae-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients.
Mutis T; Kraakman EM; Cornelisse YE; Haanen JB; Spits H; De Vries RR; Ottenhoff TH
J Immunol; 1993 May; 150(10):4641-51. PubMed ID: 8482851
[TBL] [Abstract][Full Text] [Related]
23. A new Mycobacterium species causing diffuse lepromatous leprosy.
Han XY; Seo YH; Sizer KC; Schoberle T; May GS; Spencer JS; Li W; Nair RG
Am J Clin Pathol; 2008 Dec; 130(6):856-64. PubMed ID: 19019760
[TBL] [Abstract][Full Text] [Related]
24. Antigenic similarity of a cultivable acid fast bacterium to Mycobacterium leprae.
Joshi S; Nair SC; Mahadevan PR
Indian J Med Res; 1993 Jan; 97():18-24. PubMed ID: 8486404
[TBL] [Abstract][Full Text] [Related]
25. Mycobacterium lepromatosis as Cause of Leprosy, Colombia.
Cardona-Castro N; Escobar-Builes MV; Serrano-Coll H; Adams LB; Lahiri R
Emerg Infect Dis; 2022 May; 28(5):1067-1068. PubMed ID: 35450566
[TBL] [Abstract][Full Text] [Related]
26. [LEPROMATOUS LEPROSY PRODUCED BY THE INOCULATION OF MYCOBACTERIUM LEPRAE IN TO THE FOOTPADS OF RATS FED PROOXIDANT DIETS].
BERGEL M
Dermatol Trop Ecol Geogr; 1964; 28():115-21. PubMed ID: 14201325
[No Abstract] [Full Text] [Related]
27. Effective amelioration of the Lucio phenomenon with adjuvant tofacitinib therapy in a patient with dual infection of
Patel NH; Padhiyar JK; Patel KA; Patel JR; Lakum MP; Singh I
Access Microbiol; 2023; 5(10):. PubMed ID: 37970083
[TBL] [Abstract][Full Text] [Related]
28. Case of diffuse lepromatous leprosy associated with "Mycobacterium lepromatosis".
Vera-Cabrera L; Escalante-Fuentes WG; Gomez-Flores M; Ocampo-Candiani J; Busso P; Singh P; Cole ST
J Clin Microbiol; 2011 Dec; 49(12):4366-8. PubMed ID: 22012006
[TBL] [Abstract][Full Text] [Related]
29. Severe leprosy reactions due to Mycobacterium lepromatosis.
Han XY; Jessurun J
Am J Med Sci; 2013 Jan; 345(1):65-9. PubMed ID: 23111393
[TBL] [Abstract][Full Text] [Related]
30.
Deps P; Collin SM
Front Microbiol; 2021; 12():698588. PubMed ID: 34566911
[No Abstract] [Full Text] [Related]
31. Recognition of Mycobacterium leprae antigens with antibodies present in sera from patients with lepromatous leprosy.
Islas-Rodríguez AE; Guillén-Vargas CM; Fafutis-Morris M; Alfaro-Bustamante F; Morales-Ortíz R; Gonzalez-Mendoza A; Estrada-Parra I
Int J Lepr Other Mycobact Dis; 1993 Jun; 61(2):245-9. PubMed ID: 7690388
[TBL] [Abstract][Full Text] [Related]
32. T cell responses to fractionated Mycobacterium leprae antigens in leprosy. The lepromatous nonresponder defect can be overcome in vitro by stimulation with fractionated M. leprae components.
Ottenhoff TH; Converse PJ; Gebre N; Wondimu A; Ehrenberg JP; Kiessling R
Eur J Immunol; 1989 Apr; 19(4):707-13. PubMed ID: 2659369
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of Oral Lesions in Patients With Hansen Disease.
Moronta Castellano G; Villarroel-Dorrego M; Crespo Lessmann L
Actas Dermosifiliogr (Engl Ed); 2020 Oct; 111(8):671-677. PubMed ID: 32574720
[TBL] [Abstract][Full Text] [Related]
34. Reactions to antigens from actinomycetes including Mycobacterium leprae in leprosy patients.
Ohman R; Walford C; Converse P; Ridell M
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):320-2. PubMed ID: 2071990
[No Abstract] [Full Text] [Related]
35. Elevated serum CCL2 concomitant with a reduced mycobacterium-induced response leads to disease dissemination in leprosy.
Hasan Z; Jamil B; Zaidi I; Zafar S; Khan AA; Hussain R
Scand J Immunol; 2006 Mar; 63(3):241-7. PubMed ID: 16499578
[TBL] [Abstract][Full Text] [Related]
36. T cell unresponsiveness in lepromatous leprosy.
Kamradt T
J Rheumatol; 1993 May; 20(5):904-6. PubMed ID: 8336323
[TBL] [Abstract][Full Text] [Related]
37. In vitro activation of neutrophils by suspensions of Mycobacterium leprae.
Goihman-Yahr M; Rodriguez-Ochoa G; Aranzazu N; Pinardi ME; de Gomez ME; Ocanto A; Convit J
Int J Lepr Other Mycobact Dis; 1979 Dec; 47(4):570-4. PubMed ID: 122626
[TBL] [Abstract][Full Text] [Related]
38. Leprosy patients with lepromatous disease have an up-regulated IL-8 response that is unlinked to TNF-alpha responses.
Hasan Z; Mahmood A; Zafar S; Khan AA; Hussain R
Int J Lepr Other Mycobact Dis; 2004 Mar; 72(1):35-44. PubMed ID: 15217317
[TBL] [Abstract][Full Text] [Related]
39. A 28-kDa protein from Mycobacterium leprae is a target of the human antibody response in lepromatous leprosy.
Cherayil BJ; Young RA
J Immunol; 1988 Dec; 141(12):4370-5. PubMed ID: 3058804
[TBL] [Abstract][Full Text] [Related]
40. Detection of
Ahuja M; Lavania M; Singh I; Turankar RP; Chhabra S; Narang T; Dogra S; Sengupta U
Infect Drug Resist; 2018; 11():1677-1683. PubMed ID: 30349325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
